These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization. Khersonsky O; Rosenblat M; Toker L; Yacobson S; Hugenmatter A; Silman I; Sussman JL; Aviram M; Tawfik DS Biochemistry; 2009 Jul; 48(28):6644-54. PubMed ID: 19492856 [TBL] [Abstract][Full Text] [Related]
29. Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy. Li C; Gu Q Nephrology (Carlton); 2009 Aug; 14(5):514-20. PubMed ID: 19207863 [TBL] [Abstract][Full Text] [Related]
30. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Tavori H; Khatib S; Aviram M; Vaya J Bioorg Med Chem; 2008 Aug; 16(15):7504-9. PubMed ID: 18572410 [TBL] [Abstract][Full Text] [Related]
31. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Laplaud PM; Dantoine T; Chapman MJ Clin Chem Lab Med; 1998 Jun; 36(7):431-41. PubMed ID: 9746266 [TBL] [Abstract][Full Text] [Related]
32. On the Role of Paraoxonase-1 and Chemokine Ligand 2 (C-C motif) in Metabolic Alterations Linked to Inflammation and Disease. A 2021 Update. Camps J; Castañé H; Rodríguez-Tomàs E; Baiges-Gaya G; Hernández-Aguilera A; Arenas M; Iftimie S; Joven J Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356595 [TBL] [Abstract][Full Text] [Related]
33. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228 [TBL] [Abstract][Full Text] [Related]
34. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Draganov DI Chem Biol Interact; 2010 Sep; 187(1-3):370-2. PubMed ID: 20122908 [TBL] [Abstract][Full Text] [Related]
35. The three-gene paraoxonase family: physiologic roles, actions and regulation. Précourt LP; Amre D; Denis MC; Lavoie JC; Delvin E; Seidman E; Levy E Atherosclerosis; 2011 Jan; 214(1):20-36. PubMed ID: 20934178 [TBL] [Abstract][Full Text] [Related]
36. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Gaidukov L; Viji RI; Yacobson S; Rosenblat M; Aviram M; Tawfik DS Biochemistry; 2010 Jan; 49(3):532-8. PubMed ID: 20025294 [TBL] [Abstract][Full Text] [Related]
37. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo. Gugliucci A Clin Chim Acta; 2014 Feb; 429():38-45. PubMed ID: 24280342 [TBL] [Abstract][Full Text] [Related]
38. Stability of highly purified human paraoxonase (PON1): association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s). Rochu D; Renault F; Cléry-Barraud C; Chabrière E; Masson P Biochim Biophys Acta; 2007 Jul; 1774(7):874-83. PubMed ID: 17556053 [TBL] [Abstract][Full Text] [Related]
39. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Mackness M; Durrington P; Mackness B Curr Opin Lipidol; 2004 Aug; 15(4):399-404. PubMed ID: 15243212 [TBL] [Abstract][Full Text] [Related]